Score Overview
Explore the 2021 public Archive ranking →
Where Addex Therapeutics Ltd has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ADXN does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 2.95 | — |
1 Year2025-09-29 | $ 8.94 | -67.00% |
5 Years2021-09-29 | $ 182.00 | -98.38% |
All Time2020-01-29 | $ 290.00 | -98.98% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | All Time2020-01-29 |
|---|---|---|---|---|
| Price | $ 2.95 | $ 8.94 | $ 182.00 | $ 290.00 |
| Return | — | -67.00% | -98.38% | -98.98% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in CHF
| Year | |||
|---|---|---|---|
| TTM | CHF 67.18K | -CHF 7M | |
| 2025 | CHF 29.97K | -CHF 6M | CHF 1M |
| 2024 | CHF 404.1K | CHF 7M | CHF 3M |
| 2023 | CHF 1M | -CHF 10M | CHF 3M |
| 2022 | CHF 1M | -CHF 20M | CHF 6M |
| 2021 | CHF 2M | -CHF 15M | CHF 20M |
| IPO2020 | CHF 3M | -CHF 12M | CHF 18M |
Addex Therapeutics Ltd fundamental performance
Between 2020 and 2025, revenue declined from CHF 3M to CHF 29.97K and net income went from -CHF 12M to -CHF 6M. Revenue increased in 2 of those 5 years; net income in 2.
Addex Therapeutics Ltd currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.
Membership
Explore ADXN with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
